JP2023513934A - ブドウ球菌感染症を処置するためのバクテリオファージ組成物 - Google Patents

ブドウ球菌感染症を処置するためのバクテリオファージ組成物 Download PDF

Info

Publication number
JP2023513934A
JP2023513934A JP2022549462A JP2022549462A JP2023513934A JP 2023513934 A JP2023513934 A JP 2023513934A JP 2022549462 A JP2022549462 A JP 2022549462A JP 2022549462 A JP2022549462 A JP 2022549462A JP 2023513934 A JP2023513934 A JP 2023513934A
Authority
JP
Japan
Prior art keywords
bacteriophage
seq
polynucleotide sequence
identity
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513934A5 (https=
Inventor
コラール，ステイシー・リン
バーナム，ブライアン・シー
Original Assignee
アルマタ・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルマタ・ファーマシューティカルズ・インコーポレーテッド filed Critical アルマタ・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2023513934A publication Critical patent/JP2023513934A/ja
Publication of JP2023513934A5 publication Critical patent/JP2023513934A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022549462A 2020-02-18 2021-02-18 ブドウ球菌感染症を処置するためのバクテリオファージ組成物 Pending JP2023513934A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978006P 2020-02-18 2020-02-18
US62/978,006 2020-02-18
PCT/US2021/018623 WO2021168147A1 (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection

Publications (2)

Publication Number Publication Date
JP2023513934A true JP2023513934A (ja) 2023-04-04
JP2023513934A5 JP2023513934A5 (https=) 2024-02-22

Family

ID=77272316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549462A Pending JP2023513934A (ja) 2020-02-18 2021-02-18 ブドウ球菌感染症を処置するためのバクテリオファージ組成物

Country Status (8)

Country Link
US (4) US20210252083A1 (https=)
EP (1) EP4106782A4 (https=)
JP (1) JP2023513934A (https=)
CN (1) CN115397447A (https=)
AU (1) AU2021224912A1 (https=)
CA (1) CA3171467A1 (https=)
IL (1) IL295408A (https=)
WO (1) WO2021168147A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872519B1 (en) * 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US11214773B2 (en) * 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
CN110719784A (zh) * 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
EP3372085A1 (en) * 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
CN112218659A (zh) * 2018-01-02 2021-01-12 阿玛塔制药股份有限公司 用于治疗葡萄球菌感染的治疗性噬菌体组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STAPHYLOCOCCUS PHAGE VB_SAUM_REMUS: "complete genome", GENBANK [ONLINE], vol. [検索日 2025.03.24], JPN6025012521, 2013, pages 846612 - 1, ISSN: 0005560460 *
STAPHYLOCOCCUS PHAGE VB_SAUM_ROMULUS: "complete genome", GENBANK [ONLINE], vol. [検索日 2025.03.24], JPN6025012520, 2013, pages 846613 - 1, ISSN: 0005560461 *
VANDERSTEEGEN K ET AL.: ""Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genu", JOURNAL OF VIROLOGY, vol. 87, no. 6, JPN6025012522, 9 January 2013 (2013-01-09), pages 3237 - 47, ISSN: 0005560459 *

Also Published As

Publication number Publication date
IL295408A (en) 2022-10-01
EP4106782A1 (en) 2022-12-28
WO2021168147A1 (en) 2021-08-26
US20240189373A1 (en) 2024-06-13
AU2021224912A1 (en) 2022-09-01
US20230092021A1 (en) 2023-03-23
US20260041723A1 (en) 2026-02-12
CN115397447A (zh) 2022-11-25
US20210252083A1 (en) 2021-08-19
CA3171467A1 (en) 2021-08-26
EP4106782A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US20230248789A1 (en) Therapeutic bacteriophage compositions for treating staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
CN116018154A (zh) 用于治疗假单胞菌属感染的噬菌体组合物
US20190142881A1 (en) Bacteriophage compositions and uses thereof
US20210361727A1 (en) Bacteriophage compositions for treating pseudomonas infections
Lin et al. Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii
Rezaei Bacteriophages for the treatment of resistant bacterial infectious diseases
JP2023513934A (ja) ブドウ球菌感染症を処置するためのバクテリオファージ組成物
WO2025081186A1 (en) Bacteriophage cocktail to target diverse lineages of multidrug-resistant klebsiella pneumoniae
JP7289538B2 (ja) 新規バクテリオファージおよび細菌性眼内炎治療剤
Liu et al. RETRACTED: Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin
EP3980049A1 (en) Method of treating and preventing bone and joint infections
AU2020244764A1 (en) Method of treating infective endocarditis
Lokesh et al. Phage as medicine for bacterial diseases
JP2023513934A5 (https=)
Li et al. Characterization of a novel bacteriophage Henu2 and evaluation of the synergistic antibac‑terial activity of phage–antibiotics. Antibiotics (Basel). 2021; 10 (2): 174
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
Tomas et al. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
Alattar et al. BACTERIOPHAGES AS ANTIBIOTICS ALTERNATIVES TO COMBAT MULTIDRUG RESISTANT PATHOGENS: A REVIEW ARTICLE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129